Articles by Lynda Charters

In a presentation at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting, Marjan Farid, MD, ABO, and Preeya K. Gupta, MD, offered details of clinical trials for CSF-1 ophthalmic solution, a presbyopia eye drop candidate. Results showed that nearly half of the participants treated with CSF-1 achieved a 3-line or more increase in the distance-corrected near visual acuity an hour after drop instillation on day 15.

According to an e-poster presented by Jagadesh C. Reddy, MD, and Harini Indusekar, BScOptom, at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., patients who have pre-existing DR are less likely to achieve Snellen 20/40 or better vison after cataract surgery compared with the patients with diabetes but without DR.

Blake K. Williamson, MD, MPH, MS, and coauthor Urvi Patel, BSc, presented an e-poster at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., on the efficacy of a combination eye drop comprised of an antibiotic, anti-inflammatory and lubricant as part of a postoperative treatment regimen following cataract surgery.

In an e-poster presented at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., Abdelrahman M. Elhusseiny, MD, MSc, noted a research team found that cenegermin was effective for improving the corneal healing in these pediatric patients.

Christina Weng, associate professor of ophthalmology, Baylor College of Medicine, Houston, talked about the importance of managing potential pseudophakic cystoid macular edema (CME) following cataract surgery.

About 65% of patients sought follow-up care for glaucoma after presentation to the Wills Eye Hospital emergency room (ER), according to Elliot G. Cherkas, BSc, the lead author of the study.

In patients with amblyopia, minuscule fixation eye movements play a major role with treatment, according to Fatema Ghasia, MD, associate professor of ophthalmology and director of the Vision Neuroscience and Ocular Motility Laboratory at the Cole Eye Institute at Cleveland Clinic in Ohio.

According to review, patients with mild DR at baseline fare better

According to the company, the trial will study the effect of the drug in treatment-naïve patients with diabetic macular edema (DME) who are members of underrepresented patient populations.

Device demonstrates potential as a durable, sustained-release glaucoma therapy

Despite inherent issues, clinicians still perform the procedure

The study, by investigators from the Casey Eye Institute, Oregon Health and Science University, supported the use of at-home tests during teleophthalmology care, an important point considering the significant drop in in-person VA evaluations during the pandemic.

Treatment options beginning to evolve from traditional therapies

Assembling a team of experts is key for diagnosis, treatment

Assessing cornea status can aid early recognition of disease-related changes

Investigators theorize that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.

Lower doses vs higher ones are equally effective for treating disease

Investigators have questioned the potential for the vascular density to be a biomarker for microvascular abnormalities following COVID-19 and found that longitudinal studies are needed to determine this.

Provides safe, effective injection to target choroidal, retinal tissues

Drug is prescribed as adjunctive therapy for those with glaucoma

"Tell Me Your Secrets" is the theme of the virtual April 2 event, which is expected to build on the foundation established during the first program held last fall.

Physicians offer pearls to improve visualization in eyes using retroillumination techniques

Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.

The injection of dexamethasone intraocular suspension 9% into the capsular bag may change the standard of care following cataract surgery.

Physicians find the Vivity lens offers their patients reduced glare, halos and increased spectacle independence.

Carol L. Shields, MD, and a group of colleagues conducted a retrospective case series to evaluate the likelihood of germline retinoblastoma in children with solitary unilateral retinoblastoma.

Luis Acaba-Berrocal, MD, of the Illinois Eye and Ear Infirmary in Chicago, worked with a group of colleagues to conduct a multicenter, retrospective, consecutive study of infants with ROP who had been treated with intravitreal anti-VEGF injections between 2008 and 2020 in light of the dearth of real-world data on the topic.

A team of investigators has found that the eye disease is more prevalent than first thought.

According to Claudia Perez-Straziota, MD, persistent epithelial defects do not have to live up to their name—they can be healed.

Demodex blepharitis is a virtual epidemic in the US; an estimated 20 million people have blepharitis, and of that population, almost half have Demodex. A new therapeutic is the sole treatment option that targets the disease.